Importantly, in our study, we found that human BL2 and mouse Eμ-Myc lymphomas lacking BAX expression could still be killed by both standard-of-care drugs and salvage therapies for lymphoma, indicating that tumours which acquire BAX mutations following BH3-mimetic drug treatment may still respond to chemotherapy. Here, BAX is linked to neoplasm.